Last Updated : May 10, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort ascending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Finacea | Azelaic acid | Rosacea | List | Complete | ||
| Yasmin | Drospirenone /ethinyl estradiol | Contraceptive, oral | List | Complete | ||
| Advicor | Niacin/lovastatin | Hypercholesterolemia and mixed dyslipidemia | List | Complete | ||
| Alvesco | Ciclesonide | asthma | List | Complete | ||
| Ozurdex | dexamethasone | Diabetic macular edema | Do not reimburse | Complete | ||
| Vectibix | Panitumumab | Left Sided Metastatic Colorectal Cancer (mCRC) | Do not reimburse | Complete | ||
| Lonsurf | Trifluridine and Tipiracil | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
| Lenvima | Lenvatinib | Renal Cell Carcinoma (RCC) | Do not reimburse | Complete | ||
| Nucynta | tapentadol hydrochloride | pain, severe | Do not reimburse | Complete | ||
| Steglatro | ertugliflozin | Diabetes mellitus, Type 2 | Do not reimburse | Complete |
Last Updated : May 10, 2024